TP53 allele loss, mutations and expression in malignant melanoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The tumor suppressor protein p53 plays a critical role in preventing cancer.
• Alterations in p53 are common in many cancers, but their role in malignant melanoma is less understood.

Purpose of the Study:

• To investigate p53 alterations (DNA, mRNA, protein) in malignant melanoma metastases.
• To assess the correlation between p53 status and clinical outcomes, specifically relapse-free survival.

Main Methods:

• Analysis of TP53 gene aberrations, including loss of heterozygosity (LOH) and point mutations, in tumor DNA.
• Quantification of p53 mRNA levels.
• Immunohistochemical detection of p53 protein.
• Comparison of primary and metastatic lesions.
• Assessment of MDM2 gene expression.

Main Results:

• TP53 gene aberrations were found in 23% of metastatic melanomas, with LOH being the most common abnormality.
• Increased p53 mRNA levels were observed in tumors without detectable DNA abnormalities.
• Immunohistochemically detectable p53 protein was found in several tumors lacking DNA alterations.
• p53 immunoreactivity showed a significant association with a longer relapse-free period in superficial spreading melanoma.
• MDM2 gene overexpression was rare and not consistently linked to p53 alterations.

Conclusions:

• Inactivation of the p53 pathway is not a major driver of malignant melanoma tumorigenesis.
• Wild-type p53 protein may play a role in restricting tumor cell proliferation in some melanomas.
• p53 protein expression is a potential prognostic marker for relapse-free survival in superficial spreading melanoma.